Bayer Pravachol switch program still alive
This article was originally published in The Tan Sheet
Bayer HealthCare is "working with the FDA" on its planned Rx-to-OTC switch of Bristol-Myers Squibb's cholesterol drug, Pravachol, Gary Balkema, the firm's Consumer Care Division president, says June 19. During Bayer's investor conference in Leverkusen, Germany, Balkema said gaining FDA approval for low-dose Pravachol is the division's top switch priority. "Companies that have the ability to introduce switches see some significant growth opportunities and we plan to be one of those companies," he said, adding Bayer will "explore additional switch opportunity projects." Bayer acquired U.S. marketing rights for a switch of the statin in 2004 (1"The Tan Sheet" Dec. 13, 2004, p. 5). An advisory panel review would be the second time around for pravastatin, which went before a joint panel in 2000 and failed to gain approval from the agency, as did Merck's Mevacor (lovastatin). The agency's Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees again voted against J&J and Merck's switch proposal for Mevacor in 2005 (2"The Tan Sheet" Jan. 17, 2005, p. 3). Following the vote, Merck has worked with FDA on labeling to be tested for an OTC Mevacor and on testing methodologies (3"The Tan Sheet" March 20, 2006, p. 4)...
Sign in to continue reading.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: